Hamostaseologie最新文献_第3页

Blutspende auch ohne Arztanwesenheit und aktueller Stand des Apothekenreform-Gesetzes (ApoRG). 无医生在场情况下的献血以及《药房改革法》（ApoRG）的现状。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-08-16 DOI: 10.1055/a-2288-0540

Jürgen Koscielny, Günther Kappert, Christoph Sucker

引用次数: 0

Bleeding Disorder of Unknown Cause: A Diagnosis of Exclusion. 原因不明的出血性疾病：排除性诊断。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-02-27 DOI: 10.1055/a-2263-5706

Dino Mehic, Johanna Gebhart, Ingrid Pabinger

{"title":"Bleeding Disorder of Unknown Cause: A Diagnosis of Exclusion.","authors":"Dino Mehic, Johanna Gebhart, Ingrid Pabinger","doi":"10.1055/a-2263-5706","DOIUrl":"10.1055/a-2263-5706","url":null,"abstract":"Patients with an unexplained mild to moderate bleeding tendency are diagnosed with bleeding disorder of unknown cause (BDUC), a classification reached after ruling out other mild to moderate bleeding disorders (MBD) including von Willebrand disease (VWD), platelet function defects (PFDs), coagulation factor deficiencies (CFDs), and non-hemostatic causes for bleeding. This review outlines our diagnostic approach to BDUC, a diagnosis of exclusion, drawing on current guidelines and insights from the Vienna Bleeding Biobank (VIBB). According to guidelines, we diagnose VWD based on VWF antigen and/or activity levels ≤50 IU/dL, with repeated VWF testing if VWF levels are <80 IU/dL. This has been introduced in our clinical routine after our findings of diagnostically relevant fluctuations of VWF levels in a high proportion of MBD patients. PFDs are identified through repeated abnormalities in light transmission aggregometry (LTA), flow cytometric mepacrine fluorescence, and glycoprotein expression analysis. Nevertheless, we experience diagnostic challenges with regard to reproducibility and unspecific alterations of LTA. For factor (F) VIII and FIX deficiency, a cutoff of 50% is utilized to ensure detection of mild hemophilia A or B. We apply established cutoffs for other rare CFD being aware that these do not clearly reflect the causal role of the bleeding tendency. Investigations into very rare bleeding disorders due to hyperfibrinolysis or increase in natural anticoagulants are limited to cases with a notable family history or distinct bleeding phenotypes considering cost-effectiveness. While the pathogenesis of BDUC remains unknown, further explorations of this intriguing area may reveal new mechanisms and therapeutic targets.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clot-Wave-Analyse könnte individualisierte Therapie bei Hämophilie A verbessern. 血块波分析可改善血友病 A 的个体化治疗。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-08-16 DOI: 10.1055/s-0044-1789285

引用次数: 0

Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment. 脾静脉血栓：抗凝治疗的最新进展。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-02-14 DOI: 10.1055/a-2232-5480

Scott Custo, Emma Tabone, Alexia Aquilina, Alex Gatt, Nicoletta Riva

{"title":"Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment.","authors":"Scott Custo, Emma Tabone, Alexia Aquilina, Alex Gatt, Nicoletta Riva","doi":"10.1055/a-2232-5480","DOIUrl":"10.1055/a-2232-5480","url":null,"abstract":"Splanchnic vein thrombosis (SVT) is a rare type of venous thromboembolism occurring within the splanchnic venous system. Portal vein thrombosis is the most common presentation, while Budd-Chiari syndrome is the least common. Liver cirrhosis and abdominal solid cancer are the main local risk factors for SVT, whereas myeloproliferative neoplasms are the predominant systemic risk factors. Signs and symptoms of SVT are nonspecific and include abdominal pain, gastrointestinal bleeding, and ascites. Asymptomatic SVT is not uncommon, and the majority would be detected incidentally on routine abdominal imaging performed for the follow-up of liver diseases and tumors. The management of SVT aims to prevent thrombus progression, promote vessel recanalization, and prevent recurrent venous thromboembolism. Anticoagulation should be started early in order to increase the chances of vessel recanalization and reduce the risk of portal hypertension-related complications. Direct oral anticoagulants have been included in recent guidelines, as alternatives to vitamin K antagonists, after clinical stability has been reached; however, caution is required in patients with liver or kidney dysfunction. Treatment duration is based on the presence (or absence) and type (transient vs. permanent) of risk factors. This narrative review aims to summarize the latest evidence on SVT, with a particular focus on the anticoagulant treatment in special categories of patients (e.g., liver cirrhosis, solid cancer, myeloproliferative neoplasms, pancreatitis, incidentally detected SVT, Budd-Chiari syndrome, and chronic SVT).","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rivaroxaban ist bei Malignom-assoziierten Thrombembolien nicht unterlegen. 利伐沙班治疗恶性肿瘤相关血栓栓塞症的效果并不差。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-08-16 DOI: 10.1055/s-0044-1789284

引用次数: 0

Inflammation, Sepsis, and the Coagulation System. 炎症、败血症和凝血系统。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-02-14 DOI: 10.1055/a-2202-8544

János Kappelmayer, Ildikó Beke Debreceni, Zsolt Fejes, Béla Nagy

{"title":"Inflammation, Sepsis, and the Coagulation System.","authors":"János Kappelmayer, Ildikó Beke Debreceni, Zsolt Fejes, Béla Nagy","doi":"10.1055/a-2202-8544","DOIUrl":"10.1055/a-2202-8544","url":null,"abstract":"Sepsis has been a major health problem for centuries and it is still the leading cause of hospital deaths. Several studies in the past decades have identified numerous biochemical abnormalities in severe cases, and many of these studies provide evidence of the perturbation of the hemostatic system. This can result in complications, such as disseminated intravascular coagulation that can lead to multiorgan failure. Nevertheless, large clinical studies have demonstrated that the simple approach of inhibiting the coagulation processes by any means fails to provide significant improvement in the survival of septic patients. A cause of this failure could be the fact that in sepsis the major clinical problems result not primarily from the presence of the infective agent or enhanced coagulation but from the complex dysregulated systemic host response to pathogens. If this overt reaction is not fully deciphered, appropriate interference is highly unlikely and any improvement by conventional therapeutic interventions would be limited. Cellular activation in sepsis can be targeted by novel approaches like inhibition of the heterotypic cellular interactions of blood cells by targeting surface receptors or posttranscriptional control of the hemostatic system by noncoding ribonucleic acid (RNA) molecules. Stable RNA molecules can affect the expression of several proteins. Thus, it can be anticipated that modulation of microRNA production would result in a multitude of effects that may be beneficial in septic cases. Here, we highlight some of the recent diagnostic possibilities and potential novel routes of the dysregulated host response.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Die Gesellschaft für Thrombose- und Hämostaseforschung e.V. informiert. 血栓与止血研究学会通报。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-08-16 DOI: 10.1055/s-0044-1789283

引用次数: 0

Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology. 心脏肿瘤学：医学的一门新学科及其与血液学的相关性。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-05-09 DOI: 10.1055/a-2284-5855

Andreas Spannbauer, Jutta Bergler-Klein

{"title":"Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology.","authors":"Andreas Spannbauer, Jutta Bergler-Klein","doi":"10.1055/a-2284-5855","DOIUrl":"10.1055/a-2284-5855","url":null,"abstract":"Cardio-oncology, a burgeoning subspecialty, addresses the complex interplay between cardiology and oncology, particularly in light of increased cardiovascular (CV) disease mortality in cancer patients. This review provides a comprehensive overview of cardio-oncology with a focus on the therapies used in hematological malignancies. We explore the bidirectional relationship between heart failure and cancer, emphasizing the need for collaborative care. The review discusses risk stratification, highlighting the importance of baseline CV risk assessment and personalized surveillance regimens. Primary and secondary prevention strategies, including pharmacological interventions, are outlined. The review also delves into the cardiotoxicity associated with hematological cancer therapies, focusing on anthracyclines, Bruton kinase inhibitors, BCR-ABL tyrosine kinase inhibitors, CAR-T cell therapy, immune checkpoint inhibitors, multiple myeloma treatments, and hematopoietic stem cell transplantation. We then highlight the high risk of venous and arterial thromboembolisms in cancer patients and the challenges of anticoagulation management in cardio-oncology. Finally, the review touches on the importance of long-term follow-up and appropriate screening in cancer survivors at high risk of CV morbidity and mortality, based on their CV risk profile and the type and dose of cardiotoxic therapies they received such as anthracyclines or high radiation doses.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders. THROMKIDplus患者登记和遗传性血小板疾病儿童的生物材料库。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2023-11-02 DOI: 10.1055/a-2117-4639

Matthias Ballmaier, Manuela Germeshausen, Harald Schulze, Oliver Andres

{"title":"THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders.","authors":"Matthias Ballmaier, Manuela Germeshausen, Harald Schulze, Oliver Andres","doi":"10.1055/a-2117-4639","DOIUrl":"10.1055/a-2117-4639","url":null,"abstract":"Inherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland decided to establish a patient registry with associated biomaterial banking for children. This registry is designed as a retrospective-prospective, multicenter observational study and supposed to launch in the second half of 2023. Blood smears, plasma, platelet pellets, and DNA of patients will be stored in certified biomaterial banks for future translational research projects. The main inclusion criteria are (1) diagnosis of or highly suspected IPD after assessment of a THROMKIDplus competence center and (2) patients aged 0 to 17 years. Initial and follow-up data on patient history, laboratory parameters, standardized documentation of bleeding tendency, and congenital defects are collected according to good clinical practice and current data protection acts by using the MARVIN platform, a broadly used data management system supported by the German Society for Pediatric Oncology Hematology (GPOH). The THROMKIDplus study group intends to enroll ∼200 patients retrospectively and an annual amount of ∼50 patients prospectively.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.). 心血管疾病癌症患者的抗血栓治疗：德国血液学与肿瘤内科学会 (DGHO) 和血栓与止血研究学会 (GTH e.V.) 的止血工作组提出的日常实践建议。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-07-15 DOI: 10.1055/a-2337-4025

Stefani Parmentier, Steffen Koschmieder, Larissa Henze, Martin Griesshammer, Axel Matzdorff, Tamam Bakchoul, Florian Langer, Rosa Sonja Alesci, Daniel Duerschmied, Goetz Thomalla, Hanno Riess

{"title":"Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.).","authors":"Stefani Parmentier, Steffen Koschmieder, Larissa Henze, Martin Griesshammer, Axel Matzdorff, Tamam Bakchoul, Florian Langer, Rosa Sonja Alesci, Daniel Duerschmied, Goetz Thomalla, Hanno Riess","doi":"10.1055/a-2337-4025","DOIUrl":"https://doi.org/10.1055/a-2337-4025","url":null,"abstract":"Active cancer by itself but also chemotherapy is associated with an increased risk of cardiovascular disease (CVD) and especially coronary artery disease (CAD) and atrial fibrillation (AF). The frequency of CVD, CAD, and AF varies depending on comorbidities (particularly in older patients), cancer type, and stage, as well as the anticancer therapeutic being taken. Many reports exist for anticancer drugs being associated with CVD, CAD, and AF, but robust data are often lacking. Because of this, each patient needs an individual structured approach concerning thromboembolic and bleeding risk, drug-drug interactions, as well as patient preferences to evaluate the need for anticoagulation therapy and targeting optimal symptom control. Interruption of specific cancer therapy should be avoided to reduce the potential risk of cancer progression. Nevertheless, additional factors like thrombocytopenia and anticoagulation in the elderly and frail patient with cancer cause additional challenges which need to be addressed in daily clinical management. Therefore, the aim of these recommendations is to summarize the available scientific data on antithrombotic therapy (both antiplatelet and anticoagulant therapy) in cancer patients with CVD and in cases of missing data providing guidance for optimal careful decision-making in daily routine.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0